ArticleThe British journal of dermatology2022
New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities.
Article in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Hidradenitis suppurativa and its association with obesity, smoking, and diabetes mellitus: A systematic review and meta-analysis.International wound journal · 2024Pooled it
- Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Efficacy and safety of two interleukin-17 inhibitors (bimekizumab and secukinumab) in the management of hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials.Skin health and disease · 2026Review
- Patient Journey and Unmet Needs in Hidradenitis Suppurativa: Insights from an Italian Survey.Journal of clinical medicine · 2026Article
- Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.Frontiers in immunology · 2026Review
- Global Pain Management Trends and Barriers to Care in Hidradenitis Suppurativa.Dermatology (Basel, Switzerland) · 2026Article
- [Hidradenitis Suppurativa: Most Relevant Epidemiological Characteristics of an Underdiagnosed Disease. A Cross-Sectional Study]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2025Article
- Transcriptomic Signatures and Molecular Pathways in Hidradenitis Suppurativa-A Narrative Review.International journal of molecular sciences · 2025Review
- Exploring Health Literacy among Adults with Hidradenitis Suppurativa.Dermatology (Basel, Switzerland) · 2025Article
- Comprehensive Codified Algorithms to Identify the Underestimated Burden of Hidradenitis Suppurativa in the United States.Dermatology and therapy · 2024Article
- Fibromyalgia and Skin Disorders: A Systematic Review.Journal of clinical medicine · 2024Review
- Targeting Metabolic Syndrome in Hidradenitis Suppurativa by Phytochemicals as a Potential Complementary Therapeutic Strategy.Nutrients · 2023Review
- Blood T Helper Memory Cells: A Tool for Studying Skin Inflammation in HS?International journal of molecular sciences · 2023Article
- The Development of Systemic Inflammatory Diseases in Hidradenitis Suppurativa.Diagnostics (Basel, Switzerland) · 2023Review
- Item-specific patterns of the Skindex-17 in individuals with different levels of Hidradenitis Suppurativa severity: a network analysis study.Frontiers in public health · 2023Article
- Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits.Biomedicines · 2022Review
- The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed.The British journal of dermatology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHidradenitis suppurativa (HS) is a chronic autoinflammatory skin condition and is associated with several comorbidities. Previous studies report variable prevalence rates of HS, depending on the methodology. However, the exact prevalence remains unknown.
objectivesTo estimate the prevalence of HS in a large population-based cohort in the Northern Netherlands, and to compare patients with HS to the general population, investigate characteristics and identify potential associated comorbidities.
methodsData were collected through a cross-sectional survey-based study within the Lifelines Cohort Study (n = 167 729), based on the general population located in the Northern Netherlands. A digital self-reported questionnaire was developed consisting of validated questions for determining HS.
resultsAmong 56 084 respondents, the overall prevalence of HS was 2.1% [95% confidence interval (CI) 2.0-2.2]. The respondents with HS had lower socioeconomic status than the controls (P < 0.001) and more frequently currently smoked (P < 0.001). Several new significant associations in patients with HS were revealed, such as fibromyalgia (OR 2.26, 95% CI 1.64-3.11), irritable bowel syndrome (OR 1.63, 95% CI 1.18-2.26), chronic fatigue syndrome (OR 1.72, 95% CI 1.06-2.78) and migraine (OR 1.48, 95% CI 1.11-1.96). Fibromyalgia and chronic fatigue syndrome remained significantly associated with HS in the multivariate analysis after adjusting for age, sex, body mass index, smoking status and socioeconomic status.
conclusionsOur study showed a higher prevalence of HS in the Northern Netherlands compared with the overall estimated prevalence of 1% and identified several new associated comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.